anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Budesonide
Trial phase: Not Applicable
ATC code: A07EA06 | D07AC09 | R01AD05 | R03AK07 | R03AK12 | R03AL11 | R03BA02
SMILES: CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: control of budesonide alone

Symbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide
Eligibility criteria:
Inclusion Criteria:

Subjects will be considered for inclusion in this study based on meeting all of the following criteria:

Male or female, aged 12 to 65 years
Subjects with mild to moderate asthma as determined by NHLBI 2007 guidelines
Subjects with exacerbation of their asthma symptoms by NHLBI 2007 guidelines
IgE level at study entry less than 50 IU/mL
Men and women of reproductive potential who document use of adequate contraception during the study and for 3 months after the conclusion of treatment with study drug/placebo
Historical documentation of asthma in the patient's medical record. The patient should have 6 months or more of asthma medication and management by a Stanford physician.
Women of childbearing potential who have a negative pregnancy test (urine or serum) at the time of study entry
Subject's guardians who are capable of understanding the purpose and risks of the study and who sign a statement of informed consent for the study

Exclusion Criteria:

Subjects will be ineligible for this study based on any one of the following criteria:

With a chronic or acute disease that might interfere with the evaluation of Symbicort or Pulmicort Flexhaler therapy
Pregnancy or lactation
Current or prior malignancies (excluding non-melanoma skin carcinoma or carcinoma in situ of the cervix that has been adequately treated)
History of infection with human immunodeficiency virus (HSC-1), hepatitis B virus (HBV), or hepatitis C virus (HCV); or Hepatitis A virus (HAV)
Infections that require intravenous antibiotic therapy
Significant organ dysfunction, including cardiac, renal, liver, CNS, pulmonary, vascular, gastrointestinal, endocrine, or metabolic (e.g., creatinine >1.6 mg/dL; ALT or AST > 1.5x the upper limit of normal; history of myocardial infarction, congestive heart failure, or arrhythmias within 6 months prior to study entry)
Treatment with a humanized or chimeric antibody therapy within 4 weeks prior to study entry
Treatment with any investigational drugs or therapies within 2 weeks prior to study entry
Any use of oral, systemic corticosteroids within 2 weeks prior to study entry
Intervention: Rosuvastatin Calcium
Trial phase: Phase 2
SMILES: CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1C=CC(O)CC(O)CC(=O)[O-].CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1C=CC(O)CC(O)CC(=O)[O-].[Ca+2]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 72
Group description: Participants will take Rosuvastatin 10 mg. daily for 96 weeks

Rosuvastatin 10 mg. daily for 96 weeks: Participants will take Rosuvastatin 10 mg. daily for 96 weeks.
Eligibility criteria:
Inclusion Criteria:

Clinical diagnosis of HIV Disease
Age > 18 years old
Receiving a stable ARV regimen for at least the last 12 weeks prior to study entry and cumulative duration of ARV for 12 months
Fasting LDL cholesterol < 130 mg/dl
Fasting triglycerides < 300 mg/dL
hsCRP > 2 mg/L or CD38+DR+/CD8+ > 19%
If on Vit D replacement therapy, stable regimen for > 3 months prior to study entry

Exclusion Criteria:

Women who are pregnant or breast feeding
Any active or chronic inflammatory condition
Cardiovascular disease
Current or recent (within 24 weeks of study entry) therapy with omega-3 fatty acids, fibrates, ezetimibe or statins
Uncontrolled hypothyroidism or hyperthyroidism
Uncontrolled diabetes
Use of systemic cancer chemotherapy of immunomodulating agents
Use of Anabolic agents, growth hormone, growth hormone releasing factor, or any other anabolic agents, except for stable replacement testosterone.
Use of biphosphonates or other bone therapies

Any of the following lab findings obtained within 14 days prior to the screening evaluation including the following:

AST and/or ALT > 2.5 x ULN
Hemoglobin < 9.0 g/dL
CK > 3 X ULN
Calculated creatinine clearance < 50 mL/min
Intervention: Naltrexone
Trial phase: Phase 3
ATC code: A08AA62 | N02AA56 | N07BB04
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@]([H])(C4)[C@]3(O)CCC2=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 65
Group description: Oral tablet taken once each day for up to 1 year.
Eligibility criteria:
Primary Inclusion Criteria:

Current diagnosis of DSM-IV alcohol dependence and/or diagnosis of DSM-IV opiate dependence within 3 months prior to screening
18 years or older
Desire to seek treatment for alcohol and/or opiate abuse/dependence
Agree to use contraception for the study duration if of childbearing potential
Written informed consent and willingness to perform study procedures
Stable address and phone and at least 1 source of contact information (eg, family member, significant other)

Primary Exclusion Criteria:

Presence of opiates in the urine (as determined by urine drug test) on Day 0 prior to naltrexone treatment
Clinically significant medical/psychological condition or abnormality at screening (ie, physical examination, electrocardiogram [ECG], hematology or blood chemistry evaluation, or urinalysis findings)
Clinically significant active hepatitis or hepatic failure evidenced by 1 of the following: aspartate transaminase (AST) or alanine transaminase (ALT) higher than 3 times the upper limit of normal (3xULN), hyperbilirubinemia (bilirubin >10% above ULN), creatine phosphokinase (CPK) higher than 10xULN, prolonged prothrombin time(international normalized ratio ≥1.7), ascites, or esophageal variceal disease
Manifestation of suicidal ideation, psychotic symptoms (including significant violent behavior), or psychiatric disorders that would compromise ability to complete the study
Participation in a formal methadone program currently or within prior 3 years
More than 2 prior medically supervised detoxification treatments in prior 3 years
Pregnancy or lactation
Current prescribed opiate therapy, or receipt of opiates within 7 days prior to study drug dosing, or ongoing medical condition likely to require prescribed opiate therapy during study period
Failed naloxone challenge on Day 0 (the challenge could be repeated up to 2 times, with at least 24 hours between attempts)
Participation in a clinical trial within 30 days of screening
Previous enrollment in a VIVITROL clinical trial
Receipt of any drug product administered as a gluteal injection within 180 days prior to Day 0 or anticipated need for gluteal injections during study period
Intolerance and/or hypersensitivity to naltrexone, naloxone, or polylactide-co-polymers such as polylactide-co-glycolide (PLG)
Intervention: Desflurane
Trial phase: Phase 3
ATC code: N01AB07
SMILES: FC(F)OC(F)C(F)(F)F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 38
Group description: Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Desflurane.

Sevoflurane : 1.4 to 2.5% Sevoflurane
Eligibility criteria:
Inclusion Criteria:

Male or female, 50 to 75 years of age.
Subjects with an American Society of Anesthesiologist (ASA) physical status of I to III.
Subjects able to provide written informed consent to participate in the study.
Female subjects who have a negative urine or serum pregnancy test, who have been surgically sterilized, or are postmenopausal.
Subjects scheduled for urological cystoscopic surgery under general anesthesia with LMA intubation.

Exclusion Criteria:

Subjects who are prisoners.
Subjects who have limited decision-making capacity or lack the ability to consent.
Subjects with a history of alcohol or drug abuse within the last year.
Subjects with a history of an allergic reaction, intolerance, or contraindications to any of the study medications.
Females who are pregnant or are breastfeeding.
Subjects with BMI greater than 35.
Subjects with a history of hiatal hernia or gastroesophageal reflux disease (GERD).
Subjects with a history of pharyngeal pathology.
Subjects who have participated in or are currently participating in a clinical trial of an investigational drug within 30 days prior to surgery.
Subjects with a fixed decreased pulmonary compliance, such as patients with pulmonary fibrosis.
Subjects with multiple or massive injuries, acute abdominal and/or thoracic injuries.
Subjects with any condition associated with delayed gastric emptying.
Subjects who are profoundly unconscious and who may not resist LMA insertion or have a contraindication for the use of LMA intubation.
Subjects with any condition that in the opinion of the investigator would render the subject ineligible for participation in the study, such as unstable or severe cardiovascular, pulmonary, renal, hepatic, metabolic, or endocrine disease or neuromuscular disorder.
Subjects with a history of malignant hyperthermia.
Intervention: Sevoflurane
Trial phase: Phase 3
ATC code: N01AB08
SMILES: FCOC(C(F)(F)F)C(F)(F)F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 37
Group description: Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Sevoflurane.

Desflurane : 5.4 to 7.4% desflurane
Eligibility criteria:
Inclusion Criteria:

Male or female, 50 to 75 years of age.
Subjects with an American Society of Anesthesiologist (ASA) physical status of I to III.
Subjects able to provide written informed consent to participate in the study.
Female subjects who have a negative urine or serum pregnancy test, who have been surgically sterilized, or are postmenopausal.
Subjects scheduled for urological cystoscopic surgery under general anesthesia with LMA intubation.

Exclusion Criteria:

Subjects who are prisoners.
Subjects who have limited decision-making capacity or lack the ability to consent.
Subjects with a history of alcohol or drug abuse within the last year.
Subjects with a history of an allergic reaction, intolerance, or contraindications to any of the study medications.
Females who are pregnant or are breastfeeding.
Subjects with BMI greater than 35.
Subjects with a history of hiatal hernia or gastroesophageal reflux disease (GERD).
Subjects with a history of pharyngeal pathology.
Subjects who have participated in or are currently participating in a clinical trial of an investigational drug within 30 days prior to surgery.
Subjects with a fixed decreased pulmonary compliance, such as patients with pulmonary fibrosis.
Subjects with multiple or massive injuries, acute abdominal and/or thoracic injuries.
Subjects with any condition associated with delayed gastric emptying.
Subjects who are profoundly unconscious and who may not resist LMA insertion or have a contraindication for the use of LMA intubation.
Subjects with any condition that in the opinion of the investigator would render the subject ineligible for participation in the study, such as unstable or severe cardiovascular, pulmonary, renal, hepatic, metabolic, or endocrine disease or neuromuscular disorder.
Subjects with a history of malignant hyperthermia.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 35
Group description: Normal Saline injection

Normal Saline: Single intraarticular injection of normal saline as a placebo control
Eligibility criteria:
Inclusion Criteria:

Male or Female subject
Age 18 to 70 years

In general good health as evidenced by physical examination, normal hematology, serum chemistry, and urinalysis screening laboratory results, and a negative history of significant organ system disorders. All laboratory values must be within 20% of normal ranges.

Body Mass Index (BMI) should be between '18.5 - 45.5'. The applied scale is the same for both men and women.
Blood Pressure measurements - Systolic Blood Pressure should be between 90-160mm. Hg, and Diastolic Blood Pressure between 50-90mm.Hg,
Patients with Grade 3 chronic osteoarthritis of the knee as determined by the Radiographic Criteria of Kellgren and Lawrence.
Symptom of pain for more than four (4) consecutive months and intensity of ≥ 40 and ≤ 90 on the 100-mm scale.
Patients should be cleared to use protocol specified equipment: 3T MRI.
Patients providing written informed consent after the nature of the study is fully explained and understood by the patient.

Exclusion Criteria:

Age 71 or older
Patients with abnormal hematology, serum chemistry, or urinalysis screening laboratory results.
Patients taking non-steroidal anti-inflammatory medications within 14 days of baseline visit unless washed out as per section 3.6.4 above.
Patients taking steroidal anti-inflammatory medications within 2 months of baseline visit.
Patients with a recent (within 1 year) history of drug abuse and/or a positive urine drug test at the time of screening.
Patients receiving injections to the treated knee within 2 months prior to study entry
Patients who are contraindicated for 3T MRI.
Patients who are pregnant or currently breast-feeding children.
Patients with systemic, rheumatic or inflammatory disease of the knee or chondrocalcinosis, hemochromatosis, inflammatory arthritis, necrosis of the femoral condyle, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, synovial chondromatosis, and/or history of inflammatory arthropathy.
Patients with ongoing infectious disease, including HIV and hepatitis B or C.
Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer, or Type I diabetes.
Patients participating in a study of an experimental drug or medical device within 30 days of study entry.
Patients that will be unable to comply with the requisite study follow-up and are not able to complete all of the follow-up office visits and 3T MRI exams.
Intervention: Nikethamide
Trial phase: Phase 1 | Phase 2
ATC code: R07AB02 | R07AB52
SMILES: CCN(CC)C(=O)c1cccnc1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: NiCord®: NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
Eligibility criteria:
Inclusion Criteria:

Applicable disease and eligible for myeloablative SCT
Patients must have two partially HLA-matched CBUs
Back-up stem cell source
Adequate Karnofsky Performance score or Lansky Play-Performance scale
Sufficient physiological reserves
Signed written informed consent

Exclusion Criteria:

HLA-matched related donor able to donate
Prior allogeneic HSCT
Lymphoma patients with progressive disease
Other active malignancy
Human immunodeficiency virus (HIV) infection
Active or uncontrolled infection
Active/symptoms of central nervous system (CNS) disease
Pregnancy or lactation
Intervention: BACITRACIN
Trial phase: Phase 2
ATC code: D06AX05 | J01XX10 | R02AB04
SMILES: CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 226
Group description: Bacitracin soaked sponge
Eligibility criteria:
Inclusion Criteria:

Patient having primary or revision sinus surgery. Aged 18 years or older.Patients must have middle meatus easily identified. The type of surgery will not be influenced by the participation in this study.

Exclusion Criteria:

Age less then 18
Known sensitivity to Bacitracin
Pregnancy
Intervention: Triamcinolone
Trial phase: Phase 1 | Phase 2
ATC code: A01AC01 | C05AA12 | D07AB09 | D07BB03 | D07CB01 | D07XB02 | H02AB08 | R01AD11 | R03BA06 | S01BA05 | S02CA04
SMILES: [H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Nasopore Triamcinolone soaked sponge
Eligibility criteria:
Inclusion Criteria:

Age > 18 years
Patients with early nasal polyposis

Exclusion Criteria:

Age < 18 years
Patients with active sinus infections
Patients on long term steroids
Allergy or sensitivity to steroids
Patients with Antrochoanal polyps
Patients who received topical steroids by bio-resorbable sponge or oral steroids
Intervention: Duloxetine
Trial phase: Phase 2
ATC code: N06AX21
SMILES: CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
Eligibility criteria:
Inclusion Criteria:

Study participants will be 40 men and women between the ages of 18 and 75 who provide appropriate consent and who are agreeable to study requirements
Diagnosed with mild to moderate traumatic brain injury as defined by an initial Mayo Traumatic Brain Injury Severity Scale
Have memory impairments defined by a Hopkins Verbal Learning Test delayed recall score which falls less than or equal to 1.5 standard deviation below the mean.

Exclusion Criteria:

Refusal to give informed consent
A previous Central Nervous System illness or injury, including seizure that exhibits residual symptoms.
Current post-traumatic seizure disorder
A previous diagnosis of a psychotic disorder
Current or previous (in the last 6 months) treatment history for alcohol or substance dependency
Medications affecting noradrenergic or dopaminergic systems, alpha-adrenergic antihypertensives, antidepressant, phenobarbital, Monoamine oxidase inhibitor (MAOI), scheduled benzodiazepines, psychoactive herbal supplements (including Kava, St. John's wort), or nutritional supplements or within at least 14 days of discontinuing treatment with the above medications or supplements.
A known suicide risk
A pregnant or breastfeeding woman
Uncontrolled narrow-angle glaucoma
Serious and/or unstable medical comorbidity (e.g., AIDS, cancer, history of uncontrolled hypertension or cardiovascular disease) psychological condition, or clinically significant laboratory abnormality that in the opinion of the investigator would compromise participation in the study or be likely to lead to hospitalization during the course of the study
Liver enzymes > 1.5 times upper limit of normal
Patients with end-stage renal disease (requiring dialysis) or severe renal impairment
Known hypersensitivity to duloxetine or any of the inactive ingredients
Intervention: Lactose
Trial phase: Phase 2
SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
Eligibility criteria:
Inclusion Criteria:

Study participants will be 40 men and women between the ages of 18 and 75 who provide appropriate consent and who are agreeable to study requirements
Diagnosed with mild to moderate traumatic brain injury as defined by an initial Mayo Traumatic Brain Injury Severity Scale
Have memory impairments defined by a Hopkins Verbal Learning Test delayed recall score which falls less than or equal to 1.5 standard deviation below the mean.

Exclusion Criteria:

Refusal to give informed consent
A previous Central Nervous System illness or injury, including seizure that exhibits residual symptoms.
Current post-traumatic seizure disorder
A previous diagnosis of a psychotic disorder
Current or previous (in the last 6 months) treatment history for alcohol or substance dependency
Medications affecting noradrenergic or dopaminergic systems, alpha-adrenergic antihypertensives, antidepressant, phenobarbital, Monoamine oxidase inhibitor (MAOI), scheduled benzodiazepines, psychoactive herbal supplements (including Kava, St. John's wort), or nutritional supplements or within at least 14 days of discontinuing treatment with the above medications or supplements.
A known suicide risk
A pregnant or breastfeeding woman
Uncontrolled narrow-angle glaucoma
Serious and/or unstable medical comorbidity (e.g., AIDS, cancer, history of uncontrolled hypertension or cardiovascular disease) psychological condition, or clinically significant laboratory abnormality that in the opinion of the investigator would compromise participation in the study or be likely to lead to hospitalization during the course of the study
Liver enzymes > 1.5 times upper limit of normal
Patients with end-stage renal disease (requiring dialysis) or severe renal impairment
Known hypersensitivity to duloxetine or any of the inactive ingredients
Intervention: Pioglitazone
Trial phase: Phase 4
ATC code: A10BD05 | A10BD06 | A10BD09 | A10BD12 | A10BG03
SMILES: CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: One arm of the study subjects will be treated with Pioglitazone
Eligibility criteria:
Inclusion Criteria:

Fasting plasma Glucose- 126-270
HbA1c <10%
Hematocrit >34%
Serum creatinine <1.8mg/dl
AST (aspartate aminotransferase) < 2 times upper limit of normal
ALT (Alanine aminotransferase) < 2 time upper limit of normal
Alkaline phosphatase <2 times upper limit of normal

Exclusion Criteria:

Type 1 DM
Fasting plasma glucose >270 mg/dl
Thiazolidinedione therapy
Insulin therapy in last 3 months
Congestive heart failure > NYHA (New York Heart Association) class II
History of dyspnoea on exertion
Abnormal breath sounds
EKG changes other than non-specific ST-T changes in the ECG (Electro-CardioGram) or LVH (Left Ventricular Hypertrophy)
H/O Claudication
Intervention: (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid;(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid;(9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid
Trial phase: Phase 3
SMILES: CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)O.CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O.CCC=CCC=CCC=CCCCCCCCC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 133
Group description: 1.0 g gelatin capsules containing 850 to 882 mg of EPA and DHA ethyl esters in the average ratio EPA/DHA of 0.9:1.5 The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study.
Eligibility criteria:
Inclusion Criteria:

patients with a diagnosis of non ischemic cardiomyopathy (the absence of coronary artery disease,defined as the absence of stenosis > 50%, was confirmed by angiography performed at the time of the diagnostic workup of the cardiomyopathy)
LV systolic dysfunction (defined as an EF < 45%)
Stable clinical conditions with minimal or no symptoms for at least three month
Evidence-based medical treatment at maximum tolerated target doses for at least six month

Exclusion Criteria:

presence of symptoms or evidence of CAD diagnosed through noninvasive tests;
peripheral arterial disease;
presence of congenital or primary valvular heart disease;
persistent atrial fibrillation;
inability to perform bicycle ergometry for noncardiac causes;
moderately to severely reduced functional capacity;
NYHA functional class IV;
poor acoustic windows limiting the ability to assess echocardiographic measurements;
chronic lung disease;
advanced renal disease (eGFR < 30 mL/min/1.73 m2);
advanced liver disease;
any disease limiting life expectancy to one year or less;
contraindications to study drugs;
concomitant participation in other research studies